IP Library Granted Patent US 9,908,930
Granted Patent B2
US 9,908,930 · App. 14/774,893 · Granted Mar 6, 2018

Antibodies against influenza virus hemagglutinin and uses thereof

Inventors: Peter Palese (New York, NY); Adolfo Garcia-Sastre (New York, NY); Gene Tan (New York, NY)
Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
C07K16/1018A61K47/6841G01N33/56983A61K2039/505C07K2317/33C07K2317/565C07K2317/76C07K2319/00G01N2333/11G01N2469/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,908,930
App. No.
14/774,893
Granted
Mar 6, 2018
Kind
B2
Abstract

Provided herein are antibodies that cross-react with hemagglutinin from strains of influenza virus of the same subtype or different subtypes, host cells for producing such antibodies, and kits comprising such antibodies. Also provided herein are compositions comprising antibodies that cross-react with hemagglutinin from strains of influenza virus of the same subtype or different subtypes and methods of using such antibodies to diagnose, prevent or treat influenza virus disease.

Claims (23)

1. A monoclonal antibody that binds to a hemagglutinin of an influenza A virus strain of the H1 subtype, wherein the antibody comprises

(a) a variable heavy (VH) domain having the amino acid sequence of SEQ ID NO:17;

(b) a variable light (VL) domain having the amino acid sequence of SEQ ID NO:25;

(c) a VH domain having the amino acid sequence of SEQ ID NO 17 and a VL domain having the amino acid sequence of SEQ ID NO:25; or

(d) a VH complementarity determining region (CDR)1, VH CDR2, a VH CDR3 domain, a VL CDR1, a VL CDR2, and a VL CDR3 having the amino acid sequences of SEQ ID NO:19, 21, 23, 27, 29 and 31, respectively.

2. A humanized antibody that binds to a hemagglutinin of an influenza A virus strain of subtype H1, the antibody comprising a VH complementarity determining region (CDR)1, VH CDR2, a VH CDR3 domain, a VL CDR1, a VL CDR2, and a VL CDR3 having the amino acid sequences of SEQ ID NO:19, 21, 23, 27, 29 and 31, respectively.

3. The antibody of claim 1 , wherein the influenza A virus strain is A/USSR/92/77 (H1), A/Texas/36/91 (H1), A/New Caledonia/20/99 (H1), rA/California/04/09 (H1), or A/Solomon Islands/06 (H1).

4. The antibody of claim 1 , wherein the antibody binds to a hemagglutinin from an influenza A virus strain of the H5 subtype.

5. A composition comprising the antibody of claim 1 .

6. A composition comprising the antibody of claim 2 .

7. The antibody of claim 1 , wherein the antibody is conjugated or fused to a detectable agent or therapeutic agent.

8. A kit comprising the antibody of claim 1 .

9. A method of inhibiting an influenza A virus subtype H1 comprising administering to a subject the antibody of claim 1 .

10. A method of detecting a strain of influenza A virus of the H1 subtype comprising: (a) assaying for the level of an influenza virus HA in cells or a tissue sample of a subject using the antibody of claim 1 ; and (b) comparing the level of the influenza virus HA assayed in (a) with the level of the influenza virus HA in normal tissue samples not infected with influenza virus, wherein an increase in the assayed level of influenza virus HA compared to the control level of the influenza virus antigen is indicative of the presence of a strain of influenza A virus of the H1 subtype.

11. The method of claim 9 , wherein the strain of influenza A virus of the H1 subtype is A/USSR/92/77 (H1), A/Texas/36/91 (H1), A/New Caledonia/20/99 (H1), rA/California/04/09 (H1), or A/Solomon Islands/06 (H1).

12. A method of detecting a strain of influenza A virus of the H5 subtype comprising: (a) assaying for the level of an influenza virus HA in cells or a tissue sample of a subject using the antibody of claim 4 ; and (b) comparing the level of the influenza virus HA assayed in (a) with the level of the influenza virus HA in normal tissue samples not infected with influenza virus, wherein an increase in the assayed level of influenza virus HA compared to the control level of the influenza virus antigen is indicative of the presence of a strain of influenza A virus of the H5 subtype.

13. The method of claim 12 , wherein the strain of influenza A virus of the H5 subtype is rA/Vietnam/1203/04 (H5).

14. A method for inhibiting an influenza A virus subtype H5 comprising administering to a subject the antibody of claim 1 .

15. A method for inhibiting an influenza A virus subtype H1 and an influenza A virus subtype H5 comprising administering to a subject the antibody of claim 1 .

16. The method of claim 9 , wherein the subject is a human.

17. The method of claim 14 , wherein the subject is a human.

18. The method of claim 15 , wherein the subject is a human.

19. The method of claim 15 , wherein the strain of influenza A virus of the H1 subtype is A/USSR/92/77 (H1), A/Texas/36/91 (H1), A/New Caledonia/20/99 (H1), rA/California/04/09 (H1), or A/Solomon Islands/06 (H1).

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NO. 14/744,893 PREVIOUSLY RECORDED ON REEL 038906 FRAME 0313. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT APPLICATION NUMBER SHOULD BE 14/774,893. Recorded May 14, 2019
From: PALESE, PETER; GARCIA-SASTRE, ADOLFO; TAN, GENE
To: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Reel/Frame 049179/0280 →
CONFIRMATORY LICENSE Recorded Nov 20, 2017
From: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044793/0819 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2016
From: PALESE, PETER; GARCIA-SASTRE, ADOLFO; TAN, GENE
To: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Reel/Frame 038906/0313 →
Continuity (2)
Provisional Application 61783532 · Mar 14, 2013
Related Publication 20160137721A1 · May 19, 2016